Q2 2024 13F Holders as of 6/30/2024
-
Type / Class
-
Equity / Common shares, Euro 0.12 nominal value per share
-
Shares outstanding
-
26M
-
Number of holders
-
19
-
Total 13F shares, excl. options
-
3.76M
-
Shares change
-
-1.86K
-
Total reported value, excl. options
-
$6.77M
-
Value change
-
-$68.2K
-
Put/Call ratio
-
0.43
-
Number of buys
-
8
-
Number of sells
-
-7
-
Price
-
$1.80
Significant Holders of LAVA Therapeutics NV - Common shares, Euro 0.12 nominal value per share (LVTX) as of Q2 2024
25 filings reported holding LVTX - LAVA Therapeutics NV - Common shares, Euro 0.12 nominal value per share as of Q2 2024.
LAVA Therapeutics NV - Common shares, Euro 0.12 nominal value per share (LVTX) has 19 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 3.76M shares
of 26M outstanding shares and own 14.44% of the company stock.
Largest 10 shareholders include Redmile Group, LLC (2.07M shares), Bruce & Co., Inc. (772K shares), SPHERA FUNDS MANAGEMENT LTD. (368K shares), TWO SIGMA INVESTMENTS, LP (112K shares), Alpha Wave Global, LP (87.4K shares), CITADEL ADVISORS LLC (66.2K shares), PNC Financial Services Group, Inc. (65K shares), Pathway Financial Advisors LLC (60K shares), TWO SIGMA ADVISERS, LP (31.7K shares), and XTX Topco Ltd (30.8K shares).
This table shows the top 19 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.